Crinetics Pharmaceuticals, Inc. - COMMON STOCK (CRNX)
CUSIP: 22663K107
Q2 2024 13F Holders as of 30 Jun 2024
- Type / Class
- Equity / COMMON STOCK
- Shares outstanding
- 105,000,216
- Total 13F shares
- 82,487,807
- Share change
- +2,102,377
- Total reported value
- $3,694,594,767
- Put/Call ratio
- 73%
- Price per share
- $44.79
- Number of holders
- 232
- Value change
- +$92,152,096
- Number of buys
- 147
- Number of sells
- 72
Quarterly Holders Quick Answers
What is CUSIP 22663K107?
CUSIP 22663K107 identifies CRNX - Crinetics Pharmaceuticals, Inc. - COMMON STOCK in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 22663K107:
Top shareholders of CRNX - Crinetics Pharmaceuticals, Inc. - COMMON STOCK (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BlackRock Finance, Inc. |
13F
|
Company |
5.2%
|
5,436,104
|
$254,464,027 | — | 31 Mar 2024 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
5%
|
5,226,297
|
$244,642,963 | — | 31 Mar 2024 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
4.7%
|
4,949,486
|
$231,685,440 | — | 31 Mar 2024 | |
| FMR LLC |
13F
|
Company |
4.3%
|
4,463,676
|
$208,944,693 | — | 31 Mar 2024 | |
| PERCEPTIVE ADVISORS LLC |
3/4/5
13F
|
10%+ Owner · Company |
1.4%
from 13F
|
5,321,032
|
$200,336,855 | — | 18 Apr 2022 | |
| EcoR1 Capital, LLC |
13F
|
Company |
4%
|
4,155,375
|
$194,513,104 | — | 31 Mar 2024 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
3.6%
|
3,823,218
|
$178,966,000 | — | 31 Mar 2024 | |
| VANGUARD GROUP INC |
13F
|
Company |
3.4%
|
3,575,076
|
$167,349,308 | — | 31 Mar 2024 | |
| STATE STREET CORP |
13F
|
Company |
3.1%
|
3,255,253
|
$152,378,393 | — | 31 Mar 2024 | |
| Paradigm Biocapital Advisors LP |
13F
|
Company |
3%
|
3,124,749
|
$146,269,500 | — | 31 Mar 2024 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
2.8%
|
2,971,582
|
$139,099,754 | — | 31 Mar 2024 | |
| JENNISON ASSOCIATES LLC |
13F
|
Company |
2.7%
|
2,817,854
|
$131,903,744 | — | 31 Mar 2024 | |
| T. Rowe Price Investment Management, Inc. |
13F
|
Company |
2.5%
|
2,654,729
|
$124,268,000 | — | 31 Mar 2024 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
1.9%
|
1,978,172
|
$92,526,082 | — | 31 Mar 2024 | |
| First Light Asset Management, LLC |
13F
|
Company |
1.6%
|
1,690,177
|
$79,117,185 | — | 31 Mar 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.3%
|
1,401,403
|
$65,609,383 | — | 31 Mar 2024 | |
| Artal Group S.A. |
13F
|
Company |
1.3%
|
1,390,477
|
$65,088,228 | — | 31 Mar 2024 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
1.3%
|
1,385,000
|
$64,831,850 | — | 31 Mar 2024 | |
| Cormorant Asset Management, LP |
13F
|
Company |
1.1%
|
1,150,000
|
$53,831,500 | — | 31 Mar 2024 | |
| Novo Holdings A/S |
13F
|
Company |
1%
|
1,098,600
|
$51,425,466 | — | 31 Mar 2024 | |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
|
Company |
1%
|
1,059,633
|
$49,601,421 | — | 31 Mar 2024 | |
| LORD, ABBETT & CO. LLC |
13F
|
Company |
0.92%
|
964,568
|
$45,152,000 | — | 31 Mar 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.82%
|
864,107
|
$40,448,849 | — | 31 Mar 2024 | |
| Saturn V Capital Management LP |
13F
|
Company |
0.63%
|
660,143
|
$30,901,294 | — | 31 Mar 2024 | |
| Ikarian Capital, LLC |
13F
|
Company |
0.61%
|
643,751
|
$30,133,984 | — | 31 Mar 2024 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.61%
|
640,802
|
$29,995,942 | — | 31 Mar 2024 | |
| ADAGE CAPITAL PARTNERS GP, L.L.C. |
13F
|
Company |
0.6%
|
632,133
|
$29,590,146 | — | 31 Mar 2024 | |
| Laurion Capital Management LP |
13F
|
Company |
0.6%
|
630,182
|
$29,498,819 | — | 31 Mar 2024 | |
| Ensign Peak Advisors, Inc |
13F
|
Company |
0.59%
|
621,507
|
$29,092,743 | — | 31 Mar 2024 | |
| STEMPOINT CAPITAL LP |
13F
|
Company |
0.59%
|
619,789
|
$29,012,323 | — | 31 Mar 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.58%
|
612,200
|
$28,657,082 | — | 31 Mar 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.57%
|
601,384
|
$28,150,785 | — | 31 Mar 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.53%
|
553,739
|
$25,909,791 | — | 31 Mar 2024 | |
| BNP Paribas Asset Management Holding S.A. |
13F
|
Company |
0.52%
|
542,708
|
$25,404,000 | — | 31 Mar 2024 | |
| MPM BioImpact LLC |
13F
|
Company |
0.46%
|
480,588
|
$22,496,324 | — | 31 Mar 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.46%
|
478,532
|
$22,400,083 | — | 31 Mar 2024 | |
| Fiera Capital Corp |
13F
|
Company |
0.45%
|
475,510
|
$22,258,624 | — | 31 Mar 2024 | |
| Affinity Asset Advisors, LLC |
13F
|
Company |
0.45%
|
470,000
|
$22,000,700 | — | 31 Mar 2024 | |
| Fisher Asset Management, LLC |
13F
|
Company |
0.42%
|
436,023
|
$20,410,235 | — | 31 Mar 2024 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
0.39%
|
413,209
|
$19,342,314 | — | 31 Mar 2024 | |
| GW&K Investment Management, LLC |
13F
|
Company |
0.37%
|
388,066
|
$18,165,000 | — | 31 Mar 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.36%
|
375,986
|
$17,599,906 | — | 31 Mar 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.34%
|
357,142
|
$16,717,817 | — | 31 Mar 2024 | |
| Vivo Capital, LLC |
13F
|
Company |
0.33%
|
350,000
|
$16,383,500 | — | 31 Mar 2024 | |
| Integral Health Asset Management, LLC |
13F
|
Company |
0.31%
|
325,000
|
$15,213,250 | — | 31 Mar 2024 | |
| Duquesne Family Office LLC |
13F
|
Company |
0.29%
|
309,000
|
$14,464,000 | — | 31 Mar 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.28%
|
296,478
|
$13,878,129 | — | 31 Mar 2024 | |
| Rock Springs Capital Management LP |
13F
|
Company |
0.28%
|
289,400
|
$13,546,814 | — | 31 Mar 2024 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.25%
|
265,011
|
$12,405,165 | — | 31 Mar 2024 | |
| VICTORY CAPITAL MANAGEMENT INC |
13F
|
Company |
0.24%
|
257,145
|
$12,036,957 | — | 31 Mar 2024 |
Institutional Holders of Crinetics Pharmaceuticals, Inc. - COMMON STOCK (CRNX) as of Q2 2024
As of 30 Jun 2024,
Crinetics Pharmaceuticals, Inc. - COMMON STOCK (CRNX) was held by
232 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
82,487,807 shares.
The largest 10 holders included
BlackRock Inc., Driehaus Capital Management LLC, WELLINGTON MANAGEMENT GROUP LLP, VANGUARD GROUP INC, PRICE T ROWE ASSOCIATES INC /MD/, EcoR1 Capital, LLC, FMR LLC, STATE STREET CORP, Point72 Asset Management, L.P., and JENNISON ASSOCIATES LLC.
This page lists
232
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
201
Q2 2024 holders
232
Holder diff
31
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 Value $ | Q2 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.